BIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Bio-Rad Laboratories Inc (BIO) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company's recent financial performance shows declining net income and EPS, and the technical indicators do not suggest a clear upward trend. While hedge funds are increasing their positions, there are no strong positive catalysts or trading signals to justify immediate investment.
The MACD histogram is negative (-0.614) but contracting, indicating a lack of strong momentum. RSI is neutral at 49.434, and moving averages are converging, showing no clear trend. Key resistance levels are at 290.086 and 300.786, while support levels are at 255.446 and 244.746.
Hedge funds are significantly increasing their positions, with a 333305.80% increase in buying over the last quarter.
Weak Q4 financial performance with a significant drop in net income (-200.59% YoY) and EPS (-204.22% YoY). Analysts have lowered price targets, citing weak guidance and messy margins. No recent news or congress trading data to provide additional positive sentiment.
In Q4 2025, revenue increased by 3.85% YoY to $693.2M. However, net income dropped by -200.59% YoY to $720M, and EPS fell by -204.22% YoY to 26.65. Gross margin also declined slightly by -2.89% YoY to 49.74%.
Analysts have lowered price targets recently. Wells Fargo reduced the target to $320 from $340, maintaining an Equal Weight rating, citing weak guidance. UBS lowered the target to $335 from $350 but maintained a Buy rating, noting messy margins and unexpected headwinds.
